Quarry LP Grows Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Quarry LP increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 272.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 619 shares of the medical research company’s stock after purchasing an additional 453 shares during the quarter. Quarry LP’s holdings in IQVIA were worth $131,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in IQV. NEOS Investment Management LLC increased its position in IQVIA by 70.8% in the fourth quarter. NEOS Investment Management LLC now owns 2,590 shares of the medical research company’s stock worth $599,000 after buying an additional 1,074 shares during the period. Goldman Sachs Group Inc. increased its position in IQVIA by 21.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 837,865 shares of the medical research company’s stock worth $193,865,000 after buying an additional 148,568 shares during the period. Capital Research Global Investors increased its position in IQVIA by 42.2% in the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after buying an additional 592,372 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of IQVIA by 171.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 26,868 shares of the medical research company’s stock valued at $6,217,000 after purchasing an additional 16,967 shares during the period. Finally, 1832 Asset Management L.P. increased its holdings in shares of IQVIA by 5.6% during the fourth quarter. 1832 Asset Management L.P. now owns 149,737 shares of the medical research company’s stock valued at $34,646,000 after purchasing an additional 8,000 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 2.4 %

Shares of IQV stock opened at $231.37 on Wednesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The stock’s 50 day simple moving average is $241.17 and its 200 day simple moving average is $232.92. The company has a market capitalization of $42.18 billion, a price-to-earnings ratio of 31.61, a PEG ratio of 2.25 and a beta of 1.49. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.22 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on IQV. Barclays raised their price target on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group began coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Evercore ISI lifted their target price on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $267.00.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.